KIMS Plans 51% Sarvottam Stake in ₹80 Crore Healthcare Deal

Board approves two strategic healthcare investments

Krishna Institute of Medical Sciences, or KIMS, has approved the acquisition of up to a 51% equity stake in Sarvottam Health Care Private Limited, Kakinada. The proposed investment carries an aggregate consideration of up to Rs 80 crore. Sarvottam Health Care is an operations and management, or O&M, entity in the healthcare industry. KIMS said the transaction is strategic because it is already the O&M partner of the target entity. The board approved the proposal at its meeting held on October 6, 2026. The company expects to complete the acquisition on or before October 31, 2026.

Sarvottam transaction is linked to Kakinada presence

The proposed transaction concerns Sarvottam Health Care’s presence in Kakinada, Andhra Pradesh. KIMS intends to acquire up to 51% of the target’s total paid-up equity share capital. The consideration is capped at Rs 80 crore and will be paid in cash. The acquisition price is based on a valuation report issued by BDO Valuation Advisory LLP dated October 5, 2026. The announcement does not provide a final number of shares to be acquired or a final purchase price within the approved ceiling. It also does not state that the acquisition has been completed.

Valuation report sets the consideration framework

The board’s approval allows KIMS to proceed with the acquisition subject to the stated terms and completion process. The BDO valuation report provides the basis for aggregate consideration of up to Rs 80 crore. This means the announced amount is a maximum consideration rather than confirmation of a final cash outflow. The company has identified cash as the mode of consideration. No further funding details, including internal accruals or borrowings, were disclosed in the information provided. Investors will need to await confirmation of closing and the final stake acquired.

KIMS also approves Sangli investment

Alongside the Kakinada proposal, the KIMS board approved the acquisition of a 6% stake in Ushahkal Abhinav Specialty Hospital LLP, Sangli. The consideration for this investment is Rs 15 crore. Ushahkal Abhinav Specialty Hospital is also described as an O&M entity. KIMS said this investment is strategic because it is the O&M partner of the entity. Both the Sarvottam and Ushahkal transactions are expected to be completed on or before October 31, 2026. The company did not disclose additional financial or operating details of the Sangli entity in the announcement.

Key transaction details

Why the O&M relationship matters

KIMS has described both investments as strategic, citing its existing role as O&M partner for the two entities. An O&M arrangement generally places an operator in charge of specified hospital operations and management activities under an agreement. The proposed equity investments would add ownership exposure to relationships in which KIMS already has an operational role. However, the announcement does not specify whether the transactions will alter existing O&M agreements, hospital capacity, branding, staffing, or management arrangements. It also does not disclose the financial performance of Sarvottam Health Care or Ushahkal Abhinav Specialty Hospital.

Context within KIMS’s hospital network

KIMS is an Indian healthcare company operating 12 multispecialty hospitals under the KIMS Hospitals brand, according to the company information provided. The Sarvottam proposal would extend its ownership interest in a Kakinada healthcare entity while retaining the stated O&M connection. The Sangli investment is smaller at 6%, but it follows the same strategic rationale identified by the company. The transactions indicate that KIMS is using equity investments alongside operating partnerships. The disclosures, however, do not quantify any expected impact on revenue, profit, bed capacity, or consolidated financial performance.

What the announcement means for investors

For investors, the most relevant disclosed figures are the up to Rs 80 crore consideration for Sarvottam and the Rs 15 crore consideration for Ushahkal. Together, the approved consideration amounts to up to Rs 95 crore, although the announcement does not specify the final amount that will be paid for the Sarvottam stake. The Kakinada transaction could give KIMS an ownership interest of up to 51%, while the Sangli transaction is limited to 6%. The company has set October 31, 2026, as the expected completion deadline for both deals. There is no disclosed share-price movement, earnings guidance, or financial forecast tied to the acquisitions.

Completion remains the next formal step

The board approvals mark the formal start of the acquisition process disclosed by KIMS. Completion will depend on the transactions closing by the stated deadline and on the final implementation of the approved terms. KIMS has not announced any revision to the consideration caps, stake limits, or transaction timetable. A closing update would clarify the final equity acquired and the cash consideration paid. Until then, the announcement establishes KIMS’s plan to deepen its strategic association with the Kakinada and Sangli O&M entities through equity ownership.